Peer-reviewed veterinary case report
Collagen supplements for dogs with osteoarthritis benefits and effects
By Blees, Niels R et al.·Published in Journal of animal physiology and animal nutrition·2025·Department of Clinical Sciences, Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Collagen Hydrolysates as Nutritional Support in Canine Osteoarthritis: A Narrative Review.
- Species:
- dog
Plain-English summary
A group of dogs with osteoarthritis (OA), a painful joint condition, were given a nutritional supplement called collagen hydrolysates (CH) to see if it could help reduce their limping and improve their comfort. Early results showed that dogs taking CH experienced less lameness, suggesting it may help support joint health and slow down OA progression. However, more research is needed to determine the best dosage and to confirm how effective CH really is in managing OA symptoms.
People also search for: dog osteoarthritis treatment · collagen supplements for dogs · why is my dog limping · dog joint pain relief · best diet for dogs with arthritis
Abstract
Osteoarthritis (OA) is a common disease in dogs with severe impact on their welfare. The multimodal management of OA includes feeding therapeutic diets and nutraceuticals to slow down OA progression. Collagen hydrolysates (CH) are a nutritional supplement that may exert anabolic effects on osteoarthritic joint cartilage as well as disease-modifying effects. After oral intake, CH is absorbed, mainly as amino acids, di- and tripeptides that are transported amongst others to the joint. In addition to reducing cartilage degradation, CH metabolites may reduce synovial inflammation and subchondral bone sclerosis during OA. Preliminary evidence in dogs suffering from the consequences of OA support the clinical efficacy of CH with reported reductions in lameness. However, effects on biomarker level of cartilage metabolism and inflammation are inconclusive. Additionally, current studies show a lack of standardised dosing regimens and the use of not validated outcomes. Future work should therefore elucidate further on the bioavailability of CH in dogs in order to establish adequate dosing recommendations. Furthermore, high-quality placebo-controlled randomised controlled trials are essential to dstudies have evaluated the cetermine the clinical efficacy of CH to reduce lameness, prevent OA progression and thereby improve the level of evidence.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39604106/